Natco Pharma Mekaguda API unit gets USFDA EIR
Advertisement
Hyderabad: NATCO Pharma Limited has announced that the U.S. Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for the Active Pharmaceutical Ingredient (API) facility located in Mekaguda.
The inspection was conducted by the USFDA from June 9th – June 13th, 2025.
Read also: USFDA issues one observation for Natco Pharma Mekaguda unit
Following the inspection, the company received one observation in the Form-483, which was classified as “Voluntary Action Indicated” (VAI).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.